Depth of coverage of sequencing reads across platforms and regions. by Jia-Yuan Zhang (11226467)

“…Datasets generated with DNA from CD14+ monocyte and PMBC are denoted with solid and dashed lines, respectively. Decrease of sequencing depths is not identified in immunoglobulin regions, presumably due to the relatively low fraction (5–15%) of B cells in PBMC. …”

Predictive outcomes for major and minor NKH human neurogenic mutations. by Joseph Farris (8856620)

“…Formate supplementation of dams was not undertaken with the A394V mutant mouse, since it was important to establish the attenuated disease model predicted by A394V, in absence of treatment.…”

Data_Sheet_2_Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxi... by Happy Kurnia Permatasari (13042794)

“…The lipase inhibitory activity of the extract reached 90.30 ± 0.40%, 1.75% lower than orlistat. The a-amylase inhibitory assay of the extract was 84.07 ± 5.28%, while the inhibitory activity against a-glucosidase was 81.67 ± 1.54%; both were lower than acarbose. …”

Nonlinearity-related changes to the average brain regions’ ranking. by Lazaro M. Sanchez-Rodriguez (5278139)

“…As the nonlinearity increases, the Spearman’s rho coefficients for the correlation between a ranking and both, the order corresponding to the previous nonlinearity and to the linear case, decrease. …”

Interference of weeds on Barbados gooseberry initial development by Ariany G Teixeira (12736859)

“…Weed competition led to a decrease in growth and development of Barbados gooseberry reflected in a reduction of up to 40% in yield and 23% in protein content. …”

Oxidative stress substantially increases swollen mitochondria in STHdh^Q111/Q111 cells. by Youngnam N. Jin (187014)

Optimizing the plastic injection molding process and reducing warpage through response surface methodology by Van-Long Trinh (21338532)

“…This paper demonstrates a method to reduce warpage during IMP by using a response surface methodology (RSM). …”

Human ovarian cancer cells derived from ascites exhibit increased efflux compared to cells derived from the primary tumor. by Lihong Mo (766188)

Data and code from: Farm management and landscape context shape plant diversity at wetland edges in the prairie pothole region of Canada. by David Anthony Kirk (15873941)

<i>apol1</i> morphant zebrafish embryos display generalized edema and glomerular filtration defects indicative of nephropathy. by Blair R. Anderson (765261)

“…<p>Representative live images of (A) sham-injected control larvae, and (B) <i>apol1</i> morpholino (MO) injected larvae at 5 dpf. …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Table_1_Impact of the COVID-19 Lockdown on Air Quality and Resulting Public Health Benefits in the Mexico City Metropolitan Area.DOCX by Iván Y. Hernández-Paniagua (10430552)

“…SO₂ decreased only during Phase 3 in a near-road environment. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”